Shaun G Goodman Selected Research

Unstable Angina

10/2022	Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMES.
8/2022	Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
1/2022	Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Trial.
1/2021	Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial.
1/2021	Lipid Testing, Lipid-Modifying Therapy, and PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Eligibility in 27 979 Patients With Incident Acute Coronary Syndrome.
11/2020	Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial.
1/2020	Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies.
1/2020	Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis.
1/2020	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.
11/2019	Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shaun G Goodman Research Topics

Disease

132	Acute Coronary Syndrome 10/2022 - 02/2002
116	Myocardial Infarction 10/2022 - 02/2002
80	Hemorrhage 08/2022 - 01/2003
57	ST Elevation Myocardial Infarction 01/2022 - 02/2002
52	Stroke (Strokes) 01/2022 - 02/2005
47	Heart Failure 01/2022 - 02/2002
30	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 12/2003
27	Atrial Fibrillation 01/2022 - 09/2007
26	Unstable Angina 10/2022 - 07/2004
25	Coronary Artery Disease (Coronary Atherosclerosis) 12/2021 - 02/2002
23	Thrombosis (Thrombus) 01/2022 - 11/2002
19	Ischemia 01/2022 - 01/2003
15	Coronary Disease (Coronary Heart Disease) 10/2022 - 09/2010
14	Hypertension (High Blood Pressure) 01/2022 - 07/2004
14	Infarction (Infarctions) 12/2018 - 07/2004
13	Ischemic Stroke 10/2022 - 09/2008
11	Type 2 Diabetes Mellitus (MODY) 01/2022 - 12/2010
11	Diabetes Mellitus 12/2021 - 08/2006
10	Dyslipidemias (Dyslipidemia) 01/2022 - 08/2006
8	Peripheral Arterial Disease 01/2022 - 08/2017
8	Non-ST Elevated Myocardial Infarction 06/2021 - 08/2003
6	Cardiogenic Shock 10/2017 - 05/2007
5	Chronic Renal Insufficiency 08/2022 - 09/2010
5	Transient Ischemic Attack 01/2022 - 09/2008
5	Left Ventricular Dysfunction 01/2022 - 01/2016
5	Heart Arrest (Cardiac Arrest) 12/2018 - 10/2003
4	Chest Pain (Chest Pains) 04/2019 - 02/2002
4	Myocardial Ischemia (Ischemic Heart Diseases) 01/2019 - 02/2006
4	Body Weight (Weight, Body) 02/2017 - 03/2010
3	Renal Insufficiency (Renal Failure) 01/2022 - 07/2003
3	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 04/2021 - 03/2020
3	Vascular Diseases (Vascular Disease) 03/2020 - 10/2013
3	Cerebrovascular Disorders (Cerebrovascular Occlusion) 12/2019 - 12/2007
3	Anemia 12/2018 - 11/2010
3	Shock 12/2018 - 08/2008
3	Stable Angina 01/2018 - 11/2011
3	Embolism (Embolus) 01/2018 - 03/2014
3	Obesity 11/2010 - 03/2010
2	COVID-19 01/2022 - 11/2021
2	Dyspnea (Shortness of Breath) 01/2022 - 04/2016
2	Thromboembolism 01/2022 - 01/2021

Drug/Important Bio-Agent (IBA)

40	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2022 - 07/2004
39	Clopidogrel (Plavix)FDA Link 08/2022 - 01/2003
31	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2022 - 01/2003
27	alirocumabIBA 10/2022 - 11/2014
24	TicagrelorIBA 08/2022 - 02/2012
22	omega-Chloroacetophenone (Mace)IBA 10/2022 - 12/2015
21	Heparin (Liquaemin)FDA LinkGeneric 07/2012 - 01/2003
21	Enoxaparin (Lovenox)FDA LinkGeneric 02/2012 - 02/2002
18	CreatinineIBA 12/2020 - 10/2003
15	oxidized low density lipoproteinIBA 10/2022 - 08/2006
15	Prasugrel Hydrochloride FDA Link 08/2022 - 10/2008
14	AnticoagulantsIBA 01/2022 - 12/2007
13	apixabanIBA 01/2022 - 06/2009
13	Biomarkers (Surrogate Marker)IBA 01/2019 - 06/2004
12	LDL CholesterolIBA 10/2022 - 09/2009
12	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 08/2022 - 10/2015
11	Vitamin K FDA Link 01/2022 - 01/2014
11	LipidsIBA 01/2021 - 08/2006
10	Warfarin (Coumadin)FDA LinkGeneric 01/2022 - 07/2007
10	Glycoproteins (Glycoprotein)IBA 01/2020 - 11/2002
9	Eptifibatide (Integrilin)FDA Link 11/2010 - 01/2003
8	Proprotein Convertase 9IBA 08/2022 - 11/2018
8	CholesterolIBA 01/2021 - 12/2003
7	TroponinIBA 01/2021 - 11/2004
6	Tenecteplase FDA Link 02/2018 - 08/2003
6	AntithrombinsIBA 07/2012 - 07/2004
5	Lipoproteins (Lipoprotein)IBA 08/2022 - 01/2019
5	Simendan (Levosimendan)IBA 01/2022 - 12/2016
5	Lipoprotein(a)IBA 01/2021 - 01/2020
5	Adenosine Diphosphate (ADP)IBA 04/2019 - 07/2012
5	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2013 - 07/2004
5	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 03/2010 - 08/2003
4	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2022 - 02/2006
4	Ezetimibe (Zetia)FDA Link 09/2020 - 09/2009
4	Platelet Membrane Glycoprotein IIbIBA 04/2019 - 06/2006
4	Hemoglobins (Hemoglobin)IBA 10/2018 - 03/2008
4	RivaroxabanIBA 01/2018 - 01/2014
4	Creatine Kinase (Creatine Phosphokinase)IBA 11/2009 - 07/2004
4	Platelet Membrane GlycoproteinsIBA 02/2009 - 01/2003
3	ApolipoproteinsIBA 08/2022 - 11/2018
3	Cytochrome P-450 CYP2C19IBA 12/2021 - 01/2020
3	Glucose (Dextrose)FDA LinkGeneric 09/2020 - 01/2019
3	Purinergic P2Y Receptor AntagonistsIBA 04/2019 - 09/2014
3	LDL Lipoproteins (beta Lipoproteins)IBA 11/2018 - 09/2007
3	Streptokinase FDA Link 12/2015 - 12/2007
2	Morphine (MS Contin)FDA LinkGeneric 01/2022 - 04/2019
2	Sodium-Glucose Transport ProteinsIBA 12/2021 - 11/2019

Therapy/Procedure

139	Therapeutics 08/2022 - 02/2002
69	Percutaneous Coronary Intervention 08/2022 - 08/2003
29	Stents 01/2022 - 11/2006
16	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 01/2022 - 01/2003
11	Secondary Prevention 03/2022 - 12/2007
11	Thrombolytic Therapy 01/2022 - 06/2008
4	Cardiopulmonary Bypass (Heart-Lung Bypass) 01/2022 - 12/2016
4	Blood Transfusion (Blood Transfusions) 01/2017 - 07/2004
3	Surgical Amputation (Amputations) 10/2021 - 12/2019
3	Drug Therapy (Chemotherapy) 01/2021 - 12/2010
3	Drug-Eluting Stents 01/2018 - 07/2007
2	Conservative Treatment 01/2022 - 09/2012